Anuh Pharma LimitedNSE: ANUHPHR

ANUHPHR: Q2 FY25 delivered strong sequential growth in revenue, EBITDA, and EPS, with expanded capacity

· Issued by Anuh Pharma Limited

Q2 FY25 saw 20% sequential revenue growth and 42% EBITDA growth, with EPS rising to Rs 3.00. Capacity expanded to 2200 MTPA, and new product launches and regulatory approvals support a positive outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Anuh Pharma Limited on 6ix

Earlier from Anuh Pharma

Later from Anuh Pharma

All Anuh Pharma news releases